PMID- 22055098
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20220321
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 30
IP  - 12
DP  - 2011 Dec
TI  - Long-term effects of inhaled treprostinil in patients with pulmonary arterial 
      hypertension: the Treprostinil Sodium Inhalation Used in the Management of 
      Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
PG  - 1327-33
LID - 10.1016/j.healun.2011.08.019 [doi]
AB  - BACKGROUND: Inhaled treprostinil improved functional capacity as add-on therapy 
      in the short-term management of patients with pulmonary arterial hypertension 
      (PAH). This study investigated the long-term effects of inhaled treprostinil in 
      patients concurrently receiving oral background therapy. METHODS: A total of 206 
      patients (81% women) completing the 12-week double-blind phase of the 
      Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial 
      Hypertension (TRIUMPH) study transitioned into an open-label extension. Patients 
      were assessed every 3 months for changes in 6-minute walk distance (6MWD), Borg 
      dyspnea score, New York Heart Association (NYHA) functional class, quality of 
      life (QOL) scores, and signs and symptoms of PAH. RESULTS: Patients were 
      primarily NYHA class III (86%), with a mean baseline 6MWD of 349 +/- 81 meters. A 
      median change in 6MWD of 28, 31, 32, and 18 meters in patients continuing therapy 
      was observed at 6, 12, 18, and 24 months, respectively. This effect was more 
      prominent in those patients originally allocated to active therapy in the 
      double-blind phase. Survival rates for patients remaining on therapy were 97%, 
      94%, and 91% at 12, 18, and 24 months, respectively. In addition, 82%, 74%, and 
      69% of patients maintained treatment benefit as evidenced by lack of clinical 
      worsening at 12, 18, and 24 months. The most common adverse events were known 
      effects of prostanoid therapy (headache [34%], nausea [21%], and vomiting [10%]) 
      or were due to the route of administration (cough [53%], pharyngolaryngeal pain 
      [13%], and chest pain [13%]). CONCLUSIONS: Long-term therapy with inhaled 
      treprostinil demonstrated persistent benefit for PAH patients who remained on 
      therapy for up to 24 months.
CI  - Copyright A(c) 2011 International Society for Heart and Lung Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - Benza, Raymond L
AU  - Benza RL
AD  - Allegheny General Hospital, Pittsburgh, Pennsylvania, USA. rbenza@wpahs.org
FAU - Seeger, Werner
AU  - Seeger W
FAU - McLaughlin, Vallerie V
AU  - McLaughlin VV
FAU - Channick, Richard N
AU  - Channick RN
FAU - Voswinckel, Robert
AU  - Voswinckel R
FAU - Tapson, Victor F
AU  - Tapson VF
FAU - Robbins, Ivan M
AU  - Robbins IM
FAU - Olschewski, Horst
AU  - Olschewski H
FAU - Rubin, Lewis J
AU  - Rubin LJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfonamides)
RN  - 0 (Sulfones)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - Q326023R30 (Bosentan)
RN  - RUM6K67ESG (treprostinil)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/*administration & dosage/adverse effects/*therapeutic use
MH  - Blood Pressure/physiology
MH  - Bosentan
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Epoprostenol/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Female
MH  - Headache/chemically induced/epidemiology
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/physiopathology
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced/epidemiology
MH  - Physical Endurance/physiology
MH  - Piperazines/*therapeutic use
MH  - Purines/therapeutic use
MH  - Quality of Life
MH  - Sildenafil Citrate
MH  - Sulfonamides/*therapeutic use
MH  - Sulfones/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/11/08 06:00
MHDA- 2012/05/05 06:00
CRDT- 2011/11/08 06:00
PHST- 2011/05/25 00:00 [received]
PHST- 2011/08/09 00:00 [revised]
PHST- 2011/08/29 00:00 [accepted]
PHST- 2011/11/08 06:00 [entrez]
PHST- 2011/11/08 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
AID - S1053-2498(11)01121-1 [pii]
AID - 10.1016/j.healun.2011.08.019 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2011 Dec;30(12):1327-33. doi: 
      10.1016/j.healun.2011.08.019.